The phase 1 portion of the ongoing phase 1/2 study NCT01970865 enrolled patients with ALK+ or ROS1+ NSCLC with or without BM and were treatment naïve or had disease progression after ≥1 TKIs. Here, ALK is linked to non-small cell lung carcinoma.